Clinical-scale generation of strongly CD83-expressing dendritic cells using extracorporeal photopheresis.
BACKGROUND
Many strategies are currently being pursued in order to generate mature dendritic cells (DC) to be used for immunotherapy. A potent anti-tumour influence by extracorporeal photopheresis has been documented for cutaneous T-cell lymphoma, and a major mechanism of action has been suggested to be generation of DC presenting tumour antigens.


OBJECTIVE
To determine the potential of a simple clinical photopheresis protocol for large-scale development of mature DC.


METHODS
A standard monocyte-enriched leukapheresis preparation of 10(9)-10(10) cells was derived during each of five consecutive treatment sessions of a patient with cutaneous T-cell lymphoma. The cells were incubated overnight in autologous plasma with no addition of growth medium. Cell surface lymphocyte, monocyte and DC markers were determined using multi-colour flow cytometry.


RESULTS
We find signs of activation of the CD14+ monocytes, as well as the appearance of a minor population of mature DC negative for CD14 but with strong CD83 expression.


CONCLUSIONS
With a procedure appropriate for routine clinical use, a total number of 10(6)-10(7) DC ready for patient reinfusion can be prepared within 24 h. Our findings indicate the need to further explore the capacity of photopheresis to stimulate cancer patients' anti-tumour defence reaction.
Bredberg
Anders
A
Department of Medical Microbiology, Malmö University Hospital, Lund University, Malmö, Sweden.
Jonsson
Svante
S
Lindblom
Anders
A
Björk
Peter
P
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism*; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods; D007937:Leukapheresis / Q000379:methods*; D018950:Lipopolysaccharide Receptors / Q000378:metabolism*; D008214:Lymphocytes / Q000276:immunology; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology / Q000628:therapy; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology*; D010392:Pemphigus / Q000276:immunology / Q000628:therapy; D017893:Photopheresis / Q000379:methods*; D000097802:CD83 Antigen
D015703:Antigens, CD; D007136:Immunoglobulins; D018950:Lipopolysaccharide Receptors; D008562:Membrane Glycoproteins; D000097802:CD83 Antigen